


5


CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof,



(I)


- 10 wherein R^2 , R^3 , R^4 , and R^5 are independently H, halogen, -OH, -C₁₋₃alkyl, -C₁₋₃alkoxy, -SC₁₋₂alkyl, or -CF₃, with the proviso that at least 2 of R^2 , R^3 , R^4 , and R^5 are H;
 R^6 is H or -CH₃;
 R^1 is -S(O)_nR⁷ where n is 1 or 2, -S(O)₂NHR⁸, -C(O)R⁹, -NR¹⁴R¹⁵, -C(R¹⁷)=NOR¹⁶,



15

or a 5, 6, or 7 membered heteroalkyl or heteroaryl group optionally substituted with 1 or two groups selected from the group consisting of the following substituents for carbon: C₁₋₃alkyl, -CH₂CF₃, -CF₃, F, Cl, C₁₋₂alkoxy, C₁₋₂thioalkyl, and the following substituents for nitrogen: C₁₋₃alkyl and -CH₂C₁₋₂fluoroalkyl;

- 20 R^7 is C₁₋₃alkyl or C₁₋₂fluoroalkyl;
 R^8 is C₁₋₃alkyl or -CH₂C₁₋₂fluoroalkyl;
 R^9 is C₁₋₃alkyl optionally substituted with 1-3 fluorine atoms, -NR¹⁰R¹¹, -NHNR¹²R¹³, -CH₂SO₂CH₃,



- 25 R^{10} is H or C₁₋₂alkyl;


- 5 R^{11} is H, cyclopropyl, cyclopropylmethyl, C_{3-6} alkenyl with the proviso that any unsaturation is not adjacent to the depicted nitrogen, or C_{1-6} alkyl optionally substituted with hydroxy, C_{1-3} alkoxy, or 1-3 fluorine atoms with the proviso that the carbon atom in R^{11} that is bonded to the depicted nitrogen is not bonded to either a fluorine or an oxygen;
- 10 R^{12} is H or C_{1-2} alkyl;
 R^{13} is H, C_{3-5} cycloalkyl, cyclopropylmethyl, $-SO_2CH_3$, $-C(O)CH_3$, C_{3-6} alkenyl with the proviso that any unsaturation is not adjacent to the depicted nitrogen, or C_{1-6} alkyl optionally substituted with hydroxy, C_{1-3} alkoxy, or 1-3 fluorine atoms with the proviso that the carbon atom in R^{13} that is bonded to the depicted nitrogen is not
- 15 bonded to either a fluorine or an oxygen,;
 R^{14} is H or C_{1-2} alkyl;
 R^{15} is C_{3-5} cycloalkyl, cyclopropylmethyl, C_{3-6} alkenyl with the proviso that any unsaturation is not adjacent to the depicted nitrogen, or C_{1-6} alkyl optionally substituted with hydroxy, C_{1-3} alkoxy, or 1-3 fluorine atoms with the proviso that the
- 20 carbon atom in R^{15} that is bonded to the depicted nitrogen is not bonded to either a fluorine or an oxygen;
 R^{16} is C_{1-2} alkyl;
 R^{17} is H or C_{1-3} alkyl;
 R^{20} is H; and
- 25 R^{18} , R^{19} , R^{21} , and R^{22} are independently H, halogen, hydroxy, C_{1-3} alkyl, C_{1-3} alkoxy, $-SC_{1-2}$ alkyl, or $-CF_3$ with the proviso that at least one of R^{18} , R^{19} , R^{21} , or R^{22} is other than H.

2. A compound of Claim 1 wherein R^2 , R^3 , and R^5 are H or F.


3. A compound of Claim 1 or Claim 2 wherein $R^4 = H, F, Cl, -OCH_3$, or -

4. A compound of any of Claims 1-3 wherein R^6 is H.

5. A compound of any of Claims 1-4 wherein R^1 is $-S(O)_nR^7$, $S(O)_2NHR^8$,

30

 CH₃.


35



5

where R^{23} is H, C_{1-3} alkyl, or 2,2,2-trifluoroethyl, R^{24} is H, C_{1-3} alkyl, or 2,2,2-trifluoroethyl, and R^{25} is H, methyl, or ethyl.

6. A compound of Claim 5 where R^1 is



10

where R^{23} is isopropyl or 2,2,2-trifluoroethyl, R^{24} is methyl or ethyl, and R^{25} is methyl, or ethyl.

7. A compound of Claim 5 wherein R^1 $S(O)_2NHR^8$.

15

8. A compound of Claim 7 wherein R^8 is CH_3 .

9. A compound of Claim 5 wherein R^1 is $-S(O)_nR^7$.

10. A compound of Claim 9 wherein n is 2 and R^7 is CH_3 .

20

11. A compound of Claim 1 selected from the group consisting of
 2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]-N-propylbenzamide,
 N-cyclopropyl-2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]benzamide,
 2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]-N-methylbenzamide,
 25 {2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]phenyl}(4-morpholinyl)methanone,
 2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]-N,N-diethylbenzamide,
 2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]-N-ethyl-N-methylbenzamide,
 2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]-N-methyl-N-propylbenzamide,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(1,3-oxazol-5-yl)aniline,
 30 1-{2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]phenyl}-1-ethanone,

- 5 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(2-pyrazinyl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(2-methyl-1,3-thiazol-4-yl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(1-methyl-1H-pyrazol-3-yl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(1-methyl-1H-pyrazol-5-yl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(methylsulfonyl)aniline,
 10 2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]-N-methylbenzenesulfonamide,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(1-methyl-1H-pyrrol-2-yl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(1-ethyl-1H-pyrazol-3-yl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(1-ethyl-1H-pyrazol-5-yl)aniline,
 2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]-N-ethylbenzenesulfonamide,
 15 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(1-ethyl-1H-pyrrol-2-yl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-[1-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-
 5-yl]aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(ethylsulfonyl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-5-fluoro-2-(methylsulfonyl)aniline,
 20 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-5-chloro-2-(methylsulfonyl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-5-methyl-2-(methylsulfonyl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-5-methoxy-2-(methylsulfonyl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-[1-isopropyl-1H-1,2,4-triazol-5-
 yl]aniline, and pharmaceutically acceptable salts and solvates thereof.

25

12. A compound of Claim 1 selected from the group consisting of
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-5-fluoro-2-(methylsulfonyl)aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(1-ethyl-1H-pyrazol-5-yl)aniline,
 2-[(4,5-dihydro-1H-imidazol-2-ylmethyl)amino]-N-methylbenzenesulfonamide,
 30 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-[1-(2,2,2-trifluoroethyl)-1H-1,2,4-triazol-
 5-yl]aniline,
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(methylsulfonyl)aniline, and
 pharmaceutically acceptable salts and solvates thereof.


35

13. A compound of Claim 1 selected from the group consisting of
 N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-(methylsulfonyl)aniline and
 pharmaceutically acceptable salts and solvates thereof.


- Sub
A31
14. A compound of any of Claims 1-13 wherein said compound is an alpha-1A agonist.
15. A method for prevention or treatment of an alpha-1A mediated disease or condition comprising administration of a therapeutically effective amount of a compound of any of claims 1-14.
16. The method of Claim 15 wherein said disease or condition is urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, or anorexia.
17. The method of Claim 15 wherein said disease or condition is urinary incontinence.
18. A compound according to any of Claims 1-14 for use in therapy.
- Sub
A31
19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any of Claims 1-14.
20. A pharmaceutical composition according to Claim 19 further comprising a pharmaceutically acceptable diluent or carrier.
21. Use of a compound according to any of claims 1-14 for the manufacture of a medicament for the prevention or treatment of an alpha 1A mediated disease or condition.
22. Use of a compound according to Claim 20 wherein the said disease or condition is urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, or anorexia.
23. Use according to claim 22 wherein the said disease or condition is urinary incontinence.

5

24. A process for preparing a compound as claimed in any one of claims 1 to 14 which comprises reacting a compound of formula II:



with a compound of formula III:



15

25. A process as claimed in Claim 24 wherein the reaction is carried out at a pH in the range of from 3.0 to 4.0.

26. A process as claimed in Claim 24 or 25 wherein the reaction is run in a protic solvent.

27. A process as claimed in Claim 26 wherein said protic solvent is selected from the group consisting of methanol, ethanol, methoxyethanol, isopropanol, butanol, and phenol.

25

28. A process as claimed in Claim 27 wherein the protic solvent is 2-butanol.

- 5 29. A process as claimed in any of claims 24 to 28 wherein the reaction is run at a temperature or temperatures of from 80 to 140°C.